4th Quarter - Report — BIOCOM for BIOCOM (2021)

Firm

BIOCOM

Client

BIOCOM

Income

—

Expenses

$45,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Expressed importance of intellectual property protections for the life science industry. Expressed opposition to the Administration's decision to support waiving IP protections for covid-19 vaccines under the TRIPS agreement.

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Office of Science & Technology Policy (OSTP); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Urged the Department of Commerce to ensure the availability of semiconductor chips for the medical device industry.

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); Commerce, Dept of (DOC)

Taxation/Internal Revenue Code TAX

Expressed concerns with tax provisions in the FY2022 reconciliation bill, including raising the corporate tax rate and limiting the orphan drug tax credit

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: Food & Drug Administration (FDA); SENATE; Office of Science & Technology Policy (OSTP); Commerce, Dept of (DOC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Advocated against drug pricing legislation HR3, as a stand-alone bill and as a provision in the FY2022 reconciliation package. Advocated for antimicrobial resistance legislation. Supported the Medicare Coverage Innovation Pathway at CMS and expressed concerns with its withdrawal Submitted comments to FDA on cell and gene therapy early-stage clinical trials Hosted a legislative roundtable with Rep. Garcia to discuss the life science industry Hosted a legislative roundtable with Rep. Obernolte to discuss the life science industry Hosted an executive roundtable with CDRH to discuss the digital health center of excellence Hosted an executive roundtable with OSTP to discuss health care and life science priorities and initiatives

Lobbyist	Covered position, as disclosed
LAURE FABREGA CLARK	—

Contacted: Office of Science & Technology Policy (OSTP); SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Commerce, Dept of (DOC)

Bills named: H.R. 3 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.